مباشر
IlluminaIllumina Reports Financial Results for First Quarter of Fiscal Year 2026 - PR NewswireScienceDeepfakes are everywhere. The godfather of digital forensics is fighting backEndpoints NewsFDA's oncology advisors vote against 'new paradigm' in AstraZeneca trialEndpoints NewsKrazati fails confirmatory trial in colorectal cancer, putting approval at risk10x Genomics BlogWhy 10x Genomics Stock Is Surging Today - TipRanksFierceBiotechAstraZeneca's camizestrant ambitions stumble as FDA panel rejects novel oral SERD proposalEndpoints NewsHouse panel calls to ban China trial data from FDA drug trial applicationsEndpoints NewsCourt dismisses part of Lilly lawsuit against Empower, some claims can proceedEndpoints NewsSupreme Court questions how far generics makers can go with 'skinny label' drugsIlluminaTempus AI vs. Illumina: Which Oncology Stock Is Worth Buying Now? - TradingViewMACHEREY-NAGEL GmbH & Co. KGWorld Laboratory Filter Paper - Market Analysis, Forecast, Size, Trends and Insights - IndexBoxMerck KGaAMerck KGaA taps into Remepy’s Hybrid Drug platform - The Pharma Letter
GE HealthCare ٣٠ أبريل ٢٠٢٦

GE HealthCare Just Crashed 13% on a Guidance Cut. Here’s the Case for Buying the Dip - 24/7 Wall St.

GE HealthCare Just Crashed 13% on a Guidance Cut. Here’s the Case for Buying the Dip - 24/7 Wall St.

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.